@article{8b4a09b95d7849a6afa27afa62fa712d,
title = "Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood",
abstract = "Neurofilament light chain (NfL) concentration in blood is a biomarker of neuro-axonal injury in the nervous system and there now exist several assays with high enough sensitivity to measure NfL in serum and plasma. There is a need for harmonization with the goal of creating a certified reference material (CRM) for NfL and an early step in such an effort is to determine the best matrix for the CRM. This is done in a commutability study and here the results of the first one for NfL in blood is presented. Forty paired individual serum and plasma samples were analyzed for NfL on four different analytical platforms. Neat and differently spiked serum and plasma were evaluated for their suitability as a CRM using the difference in bias approach. The correlation between the different platforms with regards to measured NfL concentrations were very high (Spearman's ρ≥0.96). Samples spiked with cerebrospinal fluid (CSF) showed higher commutability compared to samples spiked with recombinant human NfL protein and serum seems to be a better choice than plasma as the matrix for a CRM. The results from this first commutability study on NfL in serum/plasma showed that it is feasible to create a CRM for NfL in blood and that spiking should be done using CSF rather than with recombinant human NfL protein.",
keywords = "certified reference material, commutability, harmonization, neurofilament light",
author = "Ulf Andreasson and Johan Gobom and Vincent Delatour and Guy Auclair and Yoav Noam and Stephen Lee and Jason Wen and Andreas Jeromin and Burak Arslan and Aleksandra MacEski and Eline Willemse and Henrik Zetterberg and Jens Kuhle and Kaj Blennow",
note = "Funding Information: Research funding: HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018–02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer{\textquoteright}s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen f{\"o}r Gamla Tj{\"a}narinnor, Hj{\"a}rnfonden, Sweden (#FO2019-0228), the European Union{\textquoteright}s Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. JK is supported the Swiss National Research Foundation (320030_189140/1; 320030_212534). KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hj{\"a}rnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01), and the Alzheimer{\textquoteright}s Association 2021 Zenith Award (ZEN-21-848495). VD is supported by the European Metrology Programme for Innovation and Research (EMPIR) joint research project 18HLT09 “NeuroMET2” which have received funding from the EMPIR program cofinanced by the Participating States and the European Union{\textquoteright}s Horizon 2020 research and innovation program. Publisher Copyright: {\textcopyright} 2023 the author(s), published by De Gruyter, Berlin/Boston 2023.",
year = "2023",
doi = "10.1515/cclm-2022-1181",
language = "English",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
}